Consensus or Controversy, Issue 1: Clinical Investigators Provide Their Perspectives on Controversial Issues in Induction and Maintenance Therapy for Transplant-Eligible Patients with Multiple Myeloma

To see the complete question and investigator responses, move your mouse over the related topic.
Click the "Select Faculty Commentary" button to review full commentary.
Click on the tabs below to navigate between the two investigator treatment graphics and related commentary featured in this issue.

Induction Treatment
Consolidation and Maintenance Treatment

* Bortezomib schedule: Biweekly for 2 weeks on, 1 week off; weekly for 2 weeks on every 3 weeks or 3 weeks on every 4 weeks